Tranexamic Acid Spinal Fusion Study

Condition: Postoperative blood loss

Eligibility

Key Inclusion Criteria

  • At least 18 years old
  • Electively undergoing complex spinal fusion surgery 
  • Negative pregnancy test at screening

Key Exclusion Criteria

  • Allergy to tranexamic acid
  • Spinal tumor/intradural pathology
  • Ankylosing spondylitis (type of arthritis)

Full Study Name

Efficacy and Safety of Tranexamic Acid in Spinal Fusion Surgery (IRB no. 51597)

Summary

The purpose of this study is to evaluate the investigational use of a drug called tranexamic acid (TXA) during spinal fusion surgery. Significant blood loss is common in patients undergoing complex spinal fusion surgery. Researchers aim to determine whether TXA will reduce the amount of bleeding after surgery and may help to reduce the rate of blood transfusions in these patients.

Participants will be randomly assigned to one of two study groups. The first group will receive the study drug, and the second group will receive a placebo (inactive substance).

Phase

Phase III


Principal Investigator

Neel Anand, MD

Contact